Skip to main content

Table 1 Clinical characteristics and viral mutations of patients.

From: Prevalent HBV point mutations and mutation combinations at BCP/preC region and their association with liver disease progression

Group

  

Advanced liver diseases

TotalΔ

p-value

Diagnosis

ASC

CH

  

HCC

  

Patient (No.)

13

75

14

44

11

157

-

Gender (Male/Female)

4/9

56/18

12/2

34/10

10/1

116/40

0.006 b

Age (years, Mean ± SD)

28 ± 9

35 ± 12

37 ± 9

47 ± 11

51 ± 6

38 ± 13

< 0.0001*

HBV DNA titer (lg, Mean ± SD)

6 ± 2

7 ± 2

7 ± 1

7 ± 1

6 ± 1

7 ± 1

0.317*

ALT (U/L, Mean ± SD)

26 ± 24

255 ± 343

212 ± 199

107 ± 127

123 ± 151

184 ± 273

0.006*

AST (U/L, Mean ± SD)

33 ± 16

124 ± 187

136 ± 181

99 ± 104

162 ± 156

114 ± 161

0.237*

nt 1753 (m/wt)

0/13

8/67

2/12

12/32

3/8

25/132

0.053b

nt 1762 (m/wt)

1/12

51/24

14/0

32/12

10/1

108/49

< 0.0001 b

nt 1764 (m/wt)

1/12

51/24

13/1

38/6

9/2

112/45

< 0.0001 b

nt 1776 (m/wt)

0/13

3/72

0/14

5/39

0/11

8/149

0.214b

nt 1803 (m/wt)

0/13

2/73

0/14

6/38

1/10

9/148

0.082b

nt 1846 (m/wt)

0/13

9/66

1/13

6/38

2/9

18/139

0.617b

nt 1896 (m/wt)

0/13

17/58

7/7

13/31

6/5

43/114

0.009 b

Mutations≥3 (Y/N)@

0/13

26/49

10/4

24/20

6/5

66/91

0.001 b

  1. ASC, asymptomatic carrier; CH, chronic hepatitis; LF, liver failure; LC, liver cirrhosis; HCC, hepatocellular carcinoma; SD, standard deviation; Δ, samples with missing values were denoted in additional file 1, Table S1; b, chi-square test; *, One way ANOVA, @, only included sites with minor allele frequency greater than 5%.